Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... The company's blockbuster semaglutide drugs, Wegovy for weight loss and Ozempic for diabetes, are key to the company's beat.

With sales of Novo Nordisk’s obesity blockbuster Wegovy more than doubling in 2024’s fourth quarter, the Danish drugmaker feels confident that it can maintain its edge over chief rival Eli ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...